Interleukin 23: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
'''Interleukin 23''' (IL-23) is a [[cytokine]] that plays a crucial role in the [[immune system]]. It is | {{DISPLAYTITLE:Interleukin 23}} | ||
== Interleukin 23 == | |||
[[File:IL12b_Crystal_Structure.rsh.png|thumb|right|Crystal structure of IL-12, a cytokine related to IL-23]] | |||
'''Interleukin 23''' (IL-23) is a [[cytokine]] that plays a crucial role in the [[immune system]]. It is involved in the inflammatory response and is important in the pathogenesis of several [[autoimmune diseases]]. IL-23 is a member of the [[IL-12]] cytokine family and shares a common subunit with IL-12. | |||
== Structure == | == Structure == | ||
IL-23 is a heterodimeric cytokine composed of two subunits: the p19 | IL-23 is a heterodimeric cytokine composed of two subunits: the p19 subunit, which is unique to IL-23, and the p40 subunit, which is shared with IL-12. The p40 subunit is encoded by the [[IL12B]] gene. The structure of IL-23 allows it to bind to its specific receptor, the [[IL-23 receptor]], which is expressed on the surface of certain [[immune cells]]. | ||
== Function == | == Function == | ||
IL-23 is | IL-23 is primarily produced by [[dendritic cells]] and [[macrophages]]. It plays a key role in the differentiation and maintenance of [[T helper 17 cells]] (Th17 cells), which are a subset of [[T cells]] involved in the immune response against extracellular pathogens and in the development of [[autoimmune diseases]]. IL-23 promotes the production of [[pro-inflammatory cytokines]] such as [[IL-17]] and [[IL-22]], which contribute to inflammation and tissue damage in autoimmune conditions. | ||
== Role in Disease == | == Role in Disease == | ||
IL-23 | IL-23 has been implicated in the pathogenesis of several autoimmune diseases, including [[psoriasis]], [[rheumatoid arthritis]], [[inflammatory bowel disease]], and [[multiple sclerosis]]. In these conditions, IL-23 drives the inflammatory response by promoting the expansion and activation of Th17 cells, leading to chronic inflammation and tissue damage. | ||
== | == Therapeutic Target == | ||
Due to its role in autoimmune diseases, IL-23 is a target for therapeutic intervention. Several [[biologic drugs]] have been developed to inhibit IL-23 signaling, including monoclonal antibodies that specifically target the p19 subunit of IL-23. These therapies have shown efficacy in treating conditions such as psoriasis and Crohn's disease by reducing inflammation and improving clinical symptoms. | |||
== Related pages == | |||
* [[Cytokine]] | * [[Cytokine]] | ||
* [[IL-12]] | |||
* [[T helper 17 cells]] | |||
* [[Autoimmune disease]] | * [[Autoimmune disease]] | ||
[[Category:Interleukins]] | |||
[[Category: | |||
[[Category:Immunology]] | [[Category:Immunology]] | ||
Latest revision as of 06:20, 16 February 2025
Interleukin 23[edit]
Interleukin 23 (IL-23) is a cytokine that plays a crucial role in the immune system. It is involved in the inflammatory response and is important in the pathogenesis of several autoimmune diseases. IL-23 is a member of the IL-12 cytokine family and shares a common subunit with IL-12.
Structure[edit]
IL-23 is a heterodimeric cytokine composed of two subunits: the p19 subunit, which is unique to IL-23, and the p40 subunit, which is shared with IL-12. The p40 subunit is encoded by the IL12B gene. The structure of IL-23 allows it to bind to its specific receptor, the IL-23 receptor, which is expressed on the surface of certain immune cells.
Function[edit]
IL-23 is primarily produced by dendritic cells and macrophages. It plays a key role in the differentiation and maintenance of T helper 17 cells (Th17 cells), which are a subset of T cells involved in the immune response against extracellular pathogens and in the development of autoimmune diseases. IL-23 promotes the production of pro-inflammatory cytokines such as IL-17 and IL-22, which contribute to inflammation and tissue damage in autoimmune conditions.
Role in Disease[edit]
IL-23 has been implicated in the pathogenesis of several autoimmune diseases, including psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. In these conditions, IL-23 drives the inflammatory response by promoting the expansion and activation of Th17 cells, leading to chronic inflammation and tissue damage.
Therapeutic Target[edit]
Due to its role in autoimmune diseases, IL-23 is a target for therapeutic intervention. Several biologic drugs have been developed to inhibit IL-23 signaling, including monoclonal antibodies that specifically target the p19 subunit of IL-23. These therapies have shown efficacy in treating conditions such as psoriasis and Crohn's disease by reducing inflammation and improving clinical symptoms.
